# US 8,697,030 B2 · Particulate materials for radiotherapy and diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,697,030 B2
- Document ID: US8697030B2
- Status: Granted
- Kind: B2
- Application number: 13/030,778
- Filed: 2011-02-18
- Published: 2011-08-25
- Granted: 2014-04-15
- Earliest claimed: 2004-03-05
- Assignees: XL Sci-Tech, Inc.
- Applicants: Yongren Benjamin Peng; Xingye Cherry Lei
- Inventors: Yongren Benjamin Peng; Xingye Cherry Lei
- Web page: https://patentgrep.com/patent/US8697030B2

## CPC

- A61K 51/1217: {Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols}
- A61N 5/1027: {Interstitial radiation therapy}
- A61K 51/1251: {micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules}
- A61K 51/1255: {Granulates, agglomerates, microspheres}
- A61L 27/425: {of phosphorus containing material, e.g. apatite}
- A61L 27/427: {of other specific inorganic materials not covered by A61L27/422 or A61L27/425}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 35/00: Antineoplastic agents
- A61L 2300/44: Radioisotopes, radionuclides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed.

## Claims

### Claim 1

A therapeutic implant material comprising
(a) a base matrix comprising oxides, oxides containing nitrogen, nitrides, or combinations thereof;
(b) a magnetic resonance imaging (MRI) agent or x-ray opaque marker; and
(c) a therapeutic radioactive isotope or combination of radioisotopes,
wherein said implant material is non-conductive.

### Claim 2 (depends on 1)

The implant material of claim 1, wherein the therapeutic radioactive isotope or combination of radioisotopes is Y-90, Pd-103, P-32, Cs-131, Sm-153, Ho-166, Yb-169, Au-198, Re-188, Re-186, Ir-192, Lu-177, Ba-140, Se-72, I-131, I-125, Sr-90, Dy-165, Er, Tl, Sr, Gd, or combinations thereof.

### Claim 3 (depends on 1)

The implant material of claim 1, wherein the therapeutic radioactive isotope or combination of radioisotopes are distributed homogeneously throughout the implant material.

### Claim 4 (depends on 1)

The implant material of claim 1, wherein said therapeutic radioactive isotope or combination of radioisotopes is present in an amount effective for radiation therapy of a tumor.

### Claim 5 (depends on 1)

The implant material of claim 1, wherein said matrix is a particulate, microsphere, porous microsphere, hollow microsphere, microcapsule, fiber, solid fiber, small rod, particulate dispersed in biopolymers, particulate dispersed in bioresorbable sutures, particulate dispersed in biocompatible gels, particulate dispersed in other media, or combinations thereof.

### Claim 6 (depends on 1)

The implant material of claim 1, wherein said implant material is embedded or encapsulated in a non-conductive delivery vehicle.

### Claim 7 (depends on 6)

The implant material of claim 6, wherein said non-conductive delivery vehicle is a biopolymer, bioresorbable suture, injectable gel, tissue adhesive, other media, or combinations thereof.

### Claim 8 (depends on 7)

The implant material of claim 7, wherein said biopolymer is poly-l-lactic acid in the molecular weight range of 30,000 to 500,000, poly-l-lactic acid co-polymers with polyglycolic acid, polydioanone (PDS II), polyglycaprone 25 (Moncryl), polyglactin 910 (Vicryl), phenyletheretherketone (PEEK), polysulfone (PSU), polyurethane, polypropylene, silicone, polyethylene terephthalate (PET), polyphenylene oxide blends (PPO), polyphenylsulfone (PPSU), polyether sulfone (PES), polyphenylene sulfide (PPS), polyetherimide (PEI), liquid crystal polymer (LCP), or combinations thereof.

### Claim 9 (depends on 1)

The implant material of claim 1, wherein the implant material comprises a nitrogen-rich surface layer.

### Claim 10 (depends on 9)

The implant material of claim 9, wherein the nitrogen-rich surface layer comprises about 15% molar nitrogen.

### Claim 11 (depends on 1)

The implant material of claim 1, wherein the base matrix does not need or require high energy particle irradiation to convert one or more stable isotopes into radioactive isotopes.

### Claim 12 (depends on 1)

The implant material of claim 1, wherein the MRI agent is Fe, Gd, or combinations thereof.

### Claim 13 (depends on 1)

The implant material of claim 1, wherein the x-ray opaque marker is Ba, Zn, or combinations thereof.

### Claim 14 (depends on 1)

The implant material of claim 1, wherein the implant material is 100 to 1000 micrometers in diameter.

### Claim 15

A method of radiation therapy comprising administering or implanting into a patient a non-conductive implant comprising (a) a base matrix comprising oxides, oxides containing nitrogen, nitrides, or combinations thereof; (b) a magnetic resonance imaging (MRI) agent, imaging radioactive isotope, or x-ray opaque marker; and (c) a therapeutic radioactive isotope or combination of radioisotopes, wherein the implant is injected, implanted, or inserted at a tumor site and the site is a joint, prostate, breast, liver, pancreas or other soft-tissue tumor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the implant is 1 to 80 micrometers in diameter.

### Claim 17 (depends on 16)

The method of claim 16, wherein the implant is suspended in a viscous medium.

### Claim 18 (depends on 17)

The method of method of claim 17, wherein the viscous medium is pyrogen-free 85% glycerol or iodized lipiodol.

### Claim 19 (depends on 15)

The method of claim 15, further comprising real-time monitoring and/or real-time dosimetry.

### Claim 20

A therapeutic implant material comprising
(a) a base matrix comprising oxides, oxides containing nitrogen, nitrides, or combinations thereof;
(b) a therapeutic radioactive isotope; and
(c) an imaging radioactive isotope,
wherein the ratio of therapeutic radioactive isotope and imaging radioactive isotope can be controlled, and
wherein said implant material is non-conductive.

### Claim 21 (depends on 20)

The therapeutic implant material of claim 20, wherein the imaging radioactive isotope is Tc-99m or In-111.

### Claim 22 (depends on 20)

The therapeutic implant material of claim 20,
wherein the therapeutic radioactive isotope and imaging radioactive isotope are encapsulated within said base matrix.

### Claim 23 (depends on 1)

The therapeutic implant material of claim 1,
wherein the therapeutic radioactive isotope and the x-ray opaque marker are encapsulated within said base matrix.

### Claim 24 (depends on 20)

The implant material of claim 20, wherein the therapeutic radioactive isotope or combination of radioisotopes is Y-90, Pd-103, P-32, Cs-131, Sm-153, Ho-166, Yb-169, Au-198, Re-188, Re-186, Ir-192, Lu-177, Ba-140, Se-72, I-131, I-125, Sr-90, Dy-165, Er, Tl, Sr, Gd, or combinations thereof.

### Claim 25 (depends on 20)

The implant material of claim 20, wherein the therapeutic radioactive isotope or combination of radioisotopes are distributed homogeneously throughout the implant material.

### Claim 26 (depends on 20)

The implant material of claim 20, wherein said therapeutic radioactive isotope or combination of radioisotopes is present in an amount effective for radiation therapy of a tumor.

### Claim 27 (depends on 20)

The implant material of claim 20, wherein said matrix is a particulate, microsphere, porous microsphere, hollow microsphere, microcapsule, fiber, solid fiber, small rod, particulate dispersed in biopolymers, particulate dispersed in bioresorbable sutures, particulate dispersed in biocompatible gels, particulate dispersed in other media, or combinations thereof.

### Claim 28 (depends on 20)

The implant material of claim 20, wherein said implant material is embedded or encapsulated in a non-conductive delivery vehicle.

### Claim 29 (depends on 28)

The implant material of claim 28, wherein said non-conductive delivery vehicle is a biopolymer, bioresorbable suture, injectable gel, tissue adhesive, other media, or combinations thereof.

### Claim 30 (depends on 29)

The implant material of claim 29, wherein said biopolymer is poly-l-lactic acid in the molecular weight range of 30,000 to 500,000, poly-l-lactic acid co-polymers with polyglycolic acid, polydioanone (PDS II), polyglycaprone 25 (Moncryl), polyglactin 910 (Vicryl), phenyletheretherketone (PEEK), polysulfone (PSU), polyurethane, polypropylene, silicone, polyethylene terephthalate (PET), polyphenylene oxide blends (PPO), polyphenylsulfone (PPSU), polyether sulfone (PES), polyphenylene sulfide (PPS), polyetherimide (PEI), liquid crystal polymer (LCP), or combinations thereof.

### Claim 31 (depends on 20)

The implant material of claim 20, wherein the implant material comprises a nitrogen-rich surface layer.

### Claim 32 (depends on 31)

The implant material of claim 31, wherein the nitrogen-rich surface layer comprises about 15% molar nitrogen.

### Claim 33 (depends on 20)

The implant material of claim 20, wherein the base matrix does not need or require high energy particle irradiation to convert one or more stable isotopes into radioactive isotopes.

### Claim 34 (depends on 20)

The implant material of claim 20, wherein the implant material is 100 to 1000 micrometers in diameter.

### Claim 35 (depends on 15)

The method of claim 15, wherein the base matrix comprises an imaging radioactive isotope, and further wherein the ratio of therapeutic radioactive isotope and imaging radioactive isotope can be controlled.

### Claim 36 (depends on 15)

The method of claim 15, wherein the base matrix comprises an imaging radioactive isotope, and further wherein the therapeutic radioactive isotope and imaging radioactive isotope are encapsulated within said base matrix.

### Claim 37 (depends on 15)

The method of claim 15, wherein the therapeutic radioactive isotope or combination of radioisotopes is Y-90, Pd-103, P-32, Cs-131, Sm-153, Ho-166, Yb-169, Au-198, Re-188, Re-186, Ir-192, Lu-177, Ba-140, Se-72, I-131, I-125, Sr-90, Dy-165, Er, Tl, Sr, Gd, or combinations thereof.

### Claim 38 (depends on 35)

The method of claim 35, wherein the therapeutic radioactive isotope or combination of radioisotopes is Y-90, Pd-103, P-32, Cs-131, Sm-153, Ho-166, Yb-169, Au-198, Re-188, Re-186, Ir-192, Lu-177, Ba-140, Se-72, I-131, I-125, Sr-90, Dy-165, Er, Tl, Sr, Gd, or combinations thereof.

### Claim 39 (depends on 15)

The method of claim 15, wherein the base matrix comprises a MRI agent or x-ray opaque marker.

### Claim 40 (depends on 39)

The method of claim 39, wherein the MRI agent is Fe, Gd, or combinations thereof.

### Claim 41 (depends on 39)

The method of claim 39, wherein the x-ray opaque marker is Ba, Zn, or combinations thereof.
